A VAR2CSA:CSP conjugate capable of inducing dual specificity antibody responses

Research output: Contribution to journalJournal articleResearchpeer-review

Standard

A VAR2CSA:CSP conjugate capable of inducing dual specificity antibody responses. / Matondo, Sungwa; Thrane, Susan; Janitzek, Christoph Mikkel; Kavishe, Reginald Adolph ; Mwakalinga, Steven Boniface; Theander, Thor Grundtvig; Salanti, Ali; Nielsen, Morten Agertoug; Pedersen, Adam Frederik Sander.

In: African Health Sciences, Vol. 17, No. 2, 2017, p. 373-381.

Research output: Contribution to journalJournal articleResearchpeer-review

Harvard

Matondo, S, Thrane, S, Janitzek, CM, Kavishe, RA, Mwakalinga, SB, Theander, TG, Salanti, A, Nielsen, MA & Pedersen, AFS 2017, 'A VAR2CSA:CSP conjugate capable of inducing dual specificity antibody responses', African Health Sciences, vol. 17, no. 2, pp. 373-381. https://doi.org/10.4314/ahs.v17i2.11

APA

Matondo, S., Thrane, S., Janitzek, C. M., Kavishe, R. A., Mwakalinga, S. B., Theander, T. G., ... Pedersen, A. F. S. (2017). A VAR2CSA:CSP conjugate capable of inducing dual specificity antibody responses. African Health Sciences, 17(2), 373-381. https://doi.org/10.4314/ahs.v17i2.11

Vancouver

Matondo S, Thrane S, Janitzek CM, Kavishe RA, Mwakalinga SB, Theander TG et al. A VAR2CSA:CSP conjugate capable of inducing dual specificity antibody responses. African Health Sciences. 2017;17(2):373-381. https://doi.org/10.4314/ahs.v17i2.11

Author

Matondo, Sungwa ; Thrane, Susan ; Janitzek, Christoph Mikkel ; Kavishe, Reginald Adolph ; Mwakalinga, Steven Boniface ; Theander, Thor Grundtvig ; Salanti, Ali ; Nielsen, Morten Agertoug ; Pedersen, Adam Frederik Sander. / A VAR2CSA:CSP conjugate capable of inducing dual specificity antibody responses. In: African Health Sciences. 2017 ; Vol. 17, No. 2. pp. 373-381.

Bibtex

@article{40084bf85fec46e6bf6707a7d1046430,
title = "A VAR2CSA:CSP conjugate capable of inducing dual specificity antibody responses",
abstract = "Background: Vaccine antigens targeting specific P. falciparum parasite stages are under pre-clinical and clinical development. It seems plausible that vaccine with multiple specificities will offer higher protection. With this hypothesis, we exploited the Spy-Tag/SpyCatcher conjugation system to make a, post expression, dual antigen conjugate vaccine, comprising two clinically tested antigen candidates (CSP and VAR2CSA). Methods: The DBL1x-DBL2x-ID2a region of VAR2CSA was genetically fused with SpyTag at N-terminus. The full-length CSP antigen was genetically fused to C-terminal SpyCatcher peptide. The covalent interaction between SpyTag/SpyCatcher enables the formation of DBL1x-DBL2x-ID2a:CSP conjugate vaccine. Immunogenicity and quality of antibody responses induced by the conjugate vaccine, as well as a control CSP-SpyCatcher vaccine, was tested in BALB/c mice. Results: Serum samples obtained from mice immunized with the conjugate vaccine were able to recognize both untagged DBL1x-DBL2x-ID2a as well as CSP antigen. Moreover, the geometric mean anti-CSP antibody titer was 1.9-fold higher in serum (at day 35 and 55 post-first immunization) from mice immunized with the conjugate vaccine, as compared to mice receiving the control vaccine. Conclusion: The data obtained in this study serves as proof-of-concept for the simultaneous induction of antibodies directed against individual antigen components in a dual stage anti-malaria vaccine.",
keywords = "Bacterial superglue, Circumsporozoite protein, CSP-SpyCatcher, DBL1x-DBL2x-ID2a:CSP conjugate, Malaria vaccine, SpyTag-DBL1x-DBL2x-ID2a, VAR2CSA",
author = "Sungwa Matondo and Susan Thrane and Janitzek, {Christoph Mikkel} and Kavishe, {Reginald Adolph} and Mwakalinga, {Steven Boniface} and Theander, {Thor Grundtvig} and Ali Salanti and Nielsen, {Morten Agertoug} and Pedersen, {Adam Frederik Sander}",
year = "2017",
doi = "10.4314/ahs.v17i2.11",
language = "English",
volume = "17",
pages = "373--381",
journal = "African Health Sciences",
issn = "1680-6905",
publisher = "Markerere University Medical School",
number = "2",

}

RIS

TY - JOUR

T1 - A VAR2CSA:CSP conjugate capable of inducing dual specificity antibody responses

AU - Matondo, Sungwa

AU - Thrane, Susan

AU - Janitzek, Christoph Mikkel

AU - Kavishe, Reginald Adolph

AU - Mwakalinga, Steven Boniface

AU - Theander, Thor Grundtvig

AU - Salanti, Ali

AU - Nielsen, Morten Agertoug

AU - Pedersen, Adam Frederik Sander

PY - 2017

Y1 - 2017

N2 - Background: Vaccine antigens targeting specific P. falciparum parasite stages are under pre-clinical and clinical development. It seems plausible that vaccine with multiple specificities will offer higher protection. With this hypothesis, we exploited the Spy-Tag/SpyCatcher conjugation system to make a, post expression, dual antigen conjugate vaccine, comprising two clinically tested antigen candidates (CSP and VAR2CSA). Methods: The DBL1x-DBL2x-ID2a region of VAR2CSA was genetically fused with SpyTag at N-terminus. The full-length CSP antigen was genetically fused to C-terminal SpyCatcher peptide. The covalent interaction between SpyTag/SpyCatcher enables the formation of DBL1x-DBL2x-ID2a:CSP conjugate vaccine. Immunogenicity and quality of antibody responses induced by the conjugate vaccine, as well as a control CSP-SpyCatcher vaccine, was tested in BALB/c mice. Results: Serum samples obtained from mice immunized with the conjugate vaccine were able to recognize both untagged DBL1x-DBL2x-ID2a as well as CSP antigen. Moreover, the geometric mean anti-CSP antibody titer was 1.9-fold higher in serum (at day 35 and 55 post-first immunization) from mice immunized with the conjugate vaccine, as compared to mice receiving the control vaccine. Conclusion: The data obtained in this study serves as proof-of-concept for the simultaneous induction of antibodies directed against individual antigen components in a dual stage anti-malaria vaccine.

AB - Background: Vaccine antigens targeting specific P. falciparum parasite stages are under pre-clinical and clinical development. It seems plausible that vaccine with multiple specificities will offer higher protection. With this hypothesis, we exploited the Spy-Tag/SpyCatcher conjugation system to make a, post expression, dual antigen conjugate vaccine, comprising two clinically tested antigen candidates (CSP and VAR2CSA). Methods: The DBL1x-DBL2x-ID2a region of VAR2CSA was genetically fused with SpyTag at N-terminus. The full-length CSP antigen was genetically fused to C-terminal SpyCatcher peptide. The covalent interaction between SpyTag/SpyCatcher enables the formation of DBL1x-DBL2x-ID2a:CSP conjugate vaccine. Immunogenicity and quality of antibody responses induced by the conjugate vaccine, as well as a control CSP-SpyCatcher vaccine, was tested in BALB/c mice. Results: Serum samples obtained from mice immunized with the conjugate vaccine were able to recognize both untagged DBL1x-DBL2x-ID2a as well as CSP antigen. Moreover, the geometric mean anti-CSP antibody titer was 1.9-fold higher in serum (at day 35 and 55 post-first immunization) from mice immunized with the conjugate vaccine, as compared to mice receiving the control vaccine. Conclusion: The data obtained in this study serves as proof-of-concept for the simultaneous induction of antibodies directed against individual antigen components in a dual stage anti-malaria vaccine.

KW - Bacterial superglue

KW - Circumsporozoite protein

KW - CSP-SpyCatcher

KW - DBL1x-DBL2x-ID2a:CSP conjugate

KW - Malaria vaccine

KW - SpyTag-DBL1x-DBL2x-ID2a

KW - VAR2CSA

U2 - 10.4314/ahs.v17i2.11

DO - 10.4314/ahs.v17i2.11

M3 - Journal article

VL - 17

SP - 373

EP - 381

JO - African Health Sciences

JF - African Health Sciences

SN - 1680-6905

IS - 2

ER -

ID: 182093027